This company listing is no longer active
Hamilton Thorne Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Kate Torchilin
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 1.5yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
A Piece Of The Puzzle Missing From Hamilton Thorne Ltd.'s (TSE:HTL) 47% Share Price Climb
Jul 29
These 4 Measures Indicate That Hamilton Thorne (CVE:HTL) Is Using Debt Reasonably Well
Aug 15At CA$1.40, Is Hamilton Thorne Ltd. (CVE:HTL) Worth Looking At Closely?
May 25Is Hamilton Thorne (CVE:HTL) Using Too Much Debt?
Mar 30These 4 Measures Indicate That Hamilton Thorne (CVE:HTL) Is Using Debt Safely
Oct 05Should You Think About Buying Hamilton Thorne Ltd. (CVE:HTL) Now?
Jun 10Hamilton Thorne (CVE:HTL) Will Be Hoping To Turn Its Returns On Capital Around
May 15Is Hamilton Thorne (CVE:HTL) A Risky Investment?
Apr 12Estimating The Fair Value Of Hamilton Thorne Ltd. (CVE:HTL)
Mar 15When Should You Buy Hamilton Thorne Ltd. (CVE:HTL)?
Mar 01Has Hamilton Thorne (CVE:HTL) Got What It Takes To Become A Multi-Bagger?
Feb 01Announcing: Hamilton Thorne (CVE:HTL) Stock Soared An Exciting 590% In The Last Five Years
Jan 19Are Insiders Selling Hamilton Thorne Ltd. (CVE:HTL) Stock?
Jan 06What Did Hamilton Thorne's (CVE:HTL) CEO Take Home Last Year?
Dec 24
We Think Hamilton Thorne (CVE:HTL) Can Stay On Top Of Its Debt
Dec 12CEO
Kate Torchilin
less than a year
Tenure
Dr. Ekaterina Torchilin PhD, MBA, also known as Kate, is President, Chief Executive Officer and Director of Hamilton Thorne Ltd. from January 15, 2024. She served as Chief Executive Officer of Biocell Cent...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 13.2yrs | US$1.27m | 2.12% CA$ 7.3m | |
| Chief Financial Officer | 2.2yrs | US$476.26k | 0.025% CA$ 84.7k | |
| Vice President of Corporate Development | no data | US$395.95k | 0.021% CA$ 71.4k | |
| Senior VP & GM of HT Inc. | 3.5yrs | US$391.30k | no data | |
| Managing Director of Gynemed | no data | US$247.11k | no data | |
| President | less than a year | no data | no data | |
| Senior Vice President Global Operations & Sustaining Engineering and Management Rep | no data | US$165.49k | no data | |
| Director of HR | no data | no data | no data | |
| President of Embryotech Laboratories Inc | no data | no data | no data | |
| Chief Executive Officer of Gynemed | no data | US$282.51k | no data | |
| Finance Controller | no data | no data | no data |
1.5yrs
Average Tenure
Experienced Management: HTL's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 13.2yrs | US$1.27m | 2.12% CA$ 7.3m | |
| President | less than a year | no data | no data | |
| Lead Independent Director | 15.1yrs | US$113.50k | 0.32% CA$ 1.1m | |
| Independent Director | 15.1yrs | US$66.00k | 13.13% CA$ 45.3m | |
| Independent Director | 17.7yrs | US$103.50k | 0.17% CA$ 580.5k | |
| Independent Director | 2.8yrs | US$113.50k | 0.060% CA$ 206.7k | |
| Independent Director | 7.8yrs | US$66.00k | 0.095% CA$ 327.7k | |
| Independent Director | 3.8yrs | US$66.00k | 0.062% CA$ 212.6k | |
| Chairman Emeritus | 2.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.6yrs | no data | no data | |
| Independent Director | 3.8yrs | US$113.50k | 0.063% CA$ 218.9k | |
| Member of Scientific Advisory Board | 3.6yrs | no data | no data |
3.8yrs
Average Tenure
71yo
Average Age
Experienced Board: HTL's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/11/29 10:19 |
| End of Day Share Price | 2024/11/29 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hamilton Thorne Ltd. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jim Byrne | Acumen Capital Finance Partners Limited |
| Doug Cooper | Beacon Securities Limited |
| Kyle Bauser | Colliers Securities |